Previous Article | Next Article 
Infection and Immunity, October 2008, p. 4370-4377, Vol. 76, No. 10
0019-9567/08/$08.00+0 doi:10.1128/IAI.00332-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Candida albicans-Endothelial Cell Interactions: a Key Step in the Pathogenesis of Systemic Candidiasis
Sarah E. W. Grubb,1*
Craig Murdoch,1
Peter E. Sudbery,2
Stephen P. Saville,3
Jose L. Lopez-Ribot,3 and
Martin H. Thornhill1
Department of Oral & Maxillofacial Medicine and Surgery, University of Sheffield, Sheffield, United Kingdom,1
Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield, United Kingdom,2
Department of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, Texas3

INTRODUCTION
Candida albicans is a normal commensal organism of the oral
cavity, gastrointestinal tract, and vagina. Under certain circumstances,
C. albicans is capable of causing host damage (or disease) leading
to oral, vaginal, cutaneous, or systemic candidiasis. The latter
is a serious infection with a high mortality range of 33% to
54% and high morbidity in those who survive (
76). In fact, in
recent years, systemic candidal infections have become the fourth
most frequent cause of nosocomial bloodstream infections in
the United States, giving rise to an enormous associated personal
and economic cost (
79). Systemic candidiasis involves the hematogenous
spread of
C. albicans to multiple organs, including the brain,
kidneys, heart, liver, and lungs (
62). Histologically, infection
of these organs is characterized by ramifying candidal hyphae
and accompanying yeast forms that produce multiple necrotic
nodules or abscesses that result in extensive organ damage leading
to organ failure. Risk factors for systemic candidiasis include
neutropenia, intravascular catheters, hemodialysis, total parenteral
nutrition, abdominal surgery, burns, broad-spectrum antibiotics,
and corticosteroids (
63). Systemic innate immune responses by
phagocytic cells, particularly neutrophils and macrophages,
appear to play a critical role in the host defense against systemic
Candida infections, and consequently, the majority of candidal
infections occur in patients with neutropenia or defects in
neutrophil or macrophage function (
5,
55).

MORPHOGENETIC CONVERSIONS AND C. ALBICANS VIRULENCE
C. albicans is a polymorphic organism that is capable of converting
between yeast, pseudohyphal, and hyphal forms. The conventional
view was that yeast forms were associated with commensal carriage,
whereas hyphal forms were associated with disease. This was
based on evidence showing that mutant forms of
C. albicans that
were locked into the yeast form were avirulent (
50). However,
this notion was challenged by Braun et al., who found that a
tup1-deficient
C. albicans strain that was constitutively pseudohyphal
was avirulent in a murine model of systemic candidiasis (
6,
7). Although the precise nature of the association between fungal
morphogenesis and host invasion is a hotly debated topic (
30),
it is now widely accepted that it is the ability to undergo
morphogenetic conversion, rather than the morphological form
itself, that is the primary determinant of pathogenicity (
71).
The dissemination of fungal organisms in systemic candidiasis starts with their entry into the bloodstream. Given the known risk factors for systemic candidiasis, this is most likely to occur in susceptible individuals by seeding from contaminated intravascular devices, by persorption of C. albicans across the gastrointestinal mucosa, by invasion of epithelially denuded surfaces, or via trauma or surgically related inoculation (4, 11, 34). Exit from the circulation is thought to occur by adhesion and then penetration into the endothelial lining of blood vessels, except possibly in the kidney, where direct adhesion to exposed extracellular matrix components within glomerular regions may occur (45). Animal studies suggest that candidal trafficking from the circulation into the tissues occurs rapidly (1, 38, 52). This review discusses the two critical steps in the migration of C. albicans cells from the circulation into the tissues, which are (i) candidal adhesion to endothelial cells lining the blood vessels and (ii) transmigration of C. albicans across the endothelium into the tissues.

ADHESION OF C. ALBICANS TO ENDOTHELIAL CELLS
During hematogenous dissemination of
C. albicans, organisms
must first adhere to the endothelial lining of blood vessels
before transmigrating across the endothelium to invade the tissues.
However, little is known about the mechanisms involved in either
process. What is known is complicated further by conflicting
evidence concerning the roles played by yeast, pseudohyphal,
and hyphal forms of
C. albicans and the role of morphogenetic
change in the adhesion and transmigration processes.
There are currently two different theories as to how C. albicans adheres to the endothelium. The first theory proposes that cells must first undergo morphogenetic conversion to hyphal forms, which then bind to and damage the endothelial lining of blood vessels before undergoing transmigration from the circulation into the tissues. However, more recent data indicate a second possibility in which morphogenetic change is not necessary for C. albicans invasion of the tissues. In this scenario, yeast cells adhere to the endothelium and then transmigrate into the tissues without undergoing morphogenetic conversion.
The basis of the first theory is morphogenetic conversion of C. albicans to the hyphal form, and there are many lines of evidence to support this hypothesis. These include the observations that germination of C. albicans is necessary for the organism to damage endothelial cells (22, 67) and that substances that inhibit germination block C. albicans-induced endothelial cell damage (27). Moreover, the time course of candidal germination and germ tube elongation on endothelial cells parallels the time course of endothelial cell damage (20). Further evidence has come from experiments using genetically engineered forms of C. albicans with filamentation defects. The ability of these organisms to damage and invade endothelial cells is severely impaired compared to that of wild-type parent strains (64, 67).
Studies showing that germinated C. albicans cells exhibit much greater adherence to epithelial cells than do yeast forms (43) prompted suggestions that C. albicans adherence to endothelial cells might also be hypha dependent. Indeed, there is some evidence to suggest that germinated candidal forms exhibit greater endothelial cell adhesion than do yeast forms of C. albicans (66). However, it is also possible that yeast forms adhere to the endothelial surface, germinate there, and then penetrate and damage the endothelium during transmigration (22) or that yeast forms adhere and are then endocytosed before germinating within the endothelial cell to cause damage (64). Taken together, the data suggest that morphogenetic transformation is involved in endothelial cell adhesion but, more particularly, in the subsequent trans-endothelial cell migration.
Conversely, there is also evidence to suggest that morphogenetic change may not be necessary for C. albicans invasion, and this is the basis for the alternative hypothesis. In animal studies in which mice were intravenously inoculated with different mutant strains, Bendel et al. found that cells from a C. albicans mutant strain locked into the yeast form were able to leave the circulation and enter the tissues in greater numbers than those of the wild-type control (4). However, once cells were in the tissues, the ability of the wild-type strain to undergo hyphal transformation was associated with higher mortality, despite the lower fungal burden in the tissues than that with mutant yeast forms (4). Further evidence to support this theory has come from in vivo experiments investigating tissue invasion and damage, performed by Saville et al. using a genetically engineered strain of C. albicans (SSY50-B) (71). This study demonstrated that yeast cells are capable of extravasating from blood vessels into the tissues without undergoing morphogenetic change. However, once cells were in the tissues, morphogenetic conversion from yeast to hyphal forms was crucial in causing tissue damage leading to death.
Such observations have led to a hypothesis in which circulating yeast cells bind to the endothelium and then transmigrate into the tissues before undergoing the hyphal transformation that results in tissue damage. In support of this, C. albicans migration from the circulation is very rapid (80 to 90% migration within 5 min) (16, 52), whereas hyphal transformation and endothelial cell damage may take several hours (66). Furthermore, because of their more compact shape and size, yeast cells may be better adapted for free dissemination within the circulation (30). In addition, the emergence of C. glabrata and C. parapsilosis as contenders for the second most common cause of disseminated candidiasis, after C. albicans (68), indicates that the ability to form true hyphae may not be essential for tissue adhesion, invasion, and pathogenesis among Candida species (30).

CANDIDATE CANDIDA ADHESINS AND THEIR ENDOTHELIAL LIGANDS
The cell wall of
C. albicans is composed primarily of an inner
structural layer of β1,3- and β1,6-glucans and chitin
(a β1,4-linked polymer of
N-acetylglucosamine) and a matrix
primarily consisting of proteins (mannoproteins) that are heavily
glycosylated with mannose-containing polysaccharides, sometimes
called mannans (Fig.
1) (
57). These take the form of short,
linear, O-linked mannan side chains that stabilize the protein
in the cell wall (
15) and large, highly branched N-linked mannans
(
12). It is this outermost layer that represents the first point
of contact between
C. albicans and the endothelium, although
not at bud scars, where the components of the inner layers of
the cell wall are exposed (
26). Proteins and carbohydrates in
these outer layers may have a number of functions, including
the ability to act as adhesion molecules, and over recent years
several
C. albicans cell wall components with the potential
to mediate adhesion to the endothelium have been identified
(Table
1). These include proteins with integrin-like properties
(reviewed in references
32 and
36),
Candida agglutinin-like
sequence (ALS) gene products (
72,
84), and mannans (
57).
Cell wall protein adhesin candidates. (i) Integrin
Mβ2-like adhesin.
Integrin analogues first gained interest in 1991, when Gustafson
et al. found that adhesion of yeast forms of
C. albicans to
cultured monolayers of human endothelial cells was mediated
in part by a candidal protein antigenically and structurally
related to the leukocyte integrin
Mβ
2 (Mac-1, CD11b/CD18,
CR3, or iC3b receptor) (
9,
32,
48). They demonstrated the expression
of the
Mβ
2-like molecule on yeast forms of
C. albicans and showed that expression was increased by growth in 20 mM
D-glucose, as opposed to 20 mM
L-glutamine (
32,
37). Furthermore,
the adhesion of yeast forms of
C. albicans to endothelial cells
was significantly reduced by anti-
Mβ
2 antibodies or pretreatment
of the
Candida cells with purified iC3b. Expression of this
ligand may be altered at different temperatures and in different
morphogenetic forms of
C. albicans (
14,
28), and this may affect
the ability of
C. albicans to adhere to endothelium (
80).
Mβ
2 has many different ligands, including iC3b, fibrinogen, factor
X, urokinase receptor, CD14, CD23, CD54 (ICAM-1), CD102 (ICAM-2),
CD242 (ICAM-4), heparin, haptoglobin, kininogen, and various
microbial proteins (
33). Of these molecules, only ICAM-1 and
-2 are widely expressed on endothelial cells, although CD14
was recently identified on primary, but not passaged, cultures
of human umbilical vein endothelial cells (
49). There are no
data on the role of CD14, CD102, or CD242 as a possible endothelial
ligand for
C. albicans adhesion, but Yokomura et al. (
82) have
shown that anti-CD54 monoclonal antibodies can partially inhibit
the adhesion of yeast forms of
C. albicans to rat pulmonary
artery endothelial cells in vitro and significantly prolong
the survival of rats injected intravenously with
C. albicans.
In certain circumstances, it is also possible that
Mβ
2 ligands such as fibrinogen, heparin and iC3b could in turn bind
to endothelial cells and act as an intermediary in
Candida-endothelial
cell adhesion.
(ii) Integrin
vβ3- and
vβ5-like adhesins.
Two other integrin-like adhesins that may play a role in candidal adhesion to endothelium have been identified. They are homologs of the vitronectin-binding integrins
vβ3 (CD51/CD61) and
vβ5 (70, 73). Spreghini et al. (73) reported the expression of both of these adhesins on yeast forms of C. albicans, while Santoni et al. (70) showed that transformation to germ tubes was associated with a marked reduction in
vβ5-like integrin expression and an increase in
vβ3-like integrin expression. They also showed that adhesion of C. albicans germ tubes to endothelium was partially inhibited by anti-
vβ3 antibodies or an RGD sequence peptide. Heparin also inhibited germ tube adhesion, and when heparin treatment was combined with either anti-
vβ3 antibody or RGD peptide, the reduction in adhesion was greater still (70). More recently, it was shown that a candidal focal adhesion kinase-like protein may be involved in regulating yeast cell adhesion to endothelium via the
vβ3- or
vβ5-like adhesins (69) or in mediating intracellular signaling following ligand binding, much as focal adhesion kinase proteins are involved in integrin-mediated signaling in mammalian cells (10). Like its human counterpart, the candidal
vβ3-like adhesin has been shown to bind to vitronectin (70, 73), but other ligands for
vβ3 include CD31 (PECAM-1), fibronectin, fibrinogen, thrombospondin, von Willebrand factor, and RGD sequence peptides (33). CD31 is expressed by endothelial cells and could act as a direct ligand for Candida adhesion (39), while in certain circumstances it is possible that other ligands could act as a bridge in Candida-endothelial cell binding. Like its human counterpart, the
vβ5-like adhesin on C. albicans also binds vitronectin and RGD peptides (70, 73), but
vβ5 lacks a known endothelial cell target ligand and thus may not be involved directly with adherence to the endothelium.
(iii) ALS gene family.
The ALS (agglutinin-like sequence) gene family encodes a group of large glycosylphosphatidylinositol-linked cell surface glycoproteins (19). To date, eight ALS genes have been identified, including ALS1 to ALS7 and ALS9, all of which appear to have differing roles in adhesion and transmigration. These genes have gained particular interest recently, and evidence shows that ALS1-transformed Saccharomyces cerevisiae exhibits up to 100-fold greater adherence to endothelial cells (24, 25, 72), while Als1-deficient C. albicans hyphae exhibit reduced adhesion to endothelial cells (83). Similarly, S. cerevisiae transformed with ALS3 shows increased adhesion (72), while Als3-deficient hyphal forms of C. albicans exhibit defective adhesion to endothelial cells (83). The loss of Als9 from yeast forms of C. albicans (85) or the loss of Als4 and decreased expression of Als2 from 1-hour-old germ tubes (86) also inhibit the adhesion of mutant C. albicans strains to endothelial cells. In contrast, mutational analysis has shown that deletion of ALS5, ALS6, or ALS7 results in increased adhesion of yeast forms of C. albicans to endothelial cells, suggesting an antiadhesive role for these proteins (84). On the other hand, the protein Als5 has been found to mediate adhesion, along with Als1, when expressed in S. cerevisiae (72). To date, the only ligand for the ALS gene products that has been found on endothelial cells is N-cadherin, which binds to Als3 on C. albicans hyphae (65).
(iv) C4BP.
The complement protein regulator C4b binding protein (C4BP) is able to bind to both yeast and hyphal forms of C. albicans and is predominantly localized at the tip of the germ tube on hyphae (53). This binding is normally regarded as a survival mechanism that inhibits complement activation and the attachment of opsonins to the microbial surface. However, it may also enhance the adhesion of yeast forms of C. albicans to endothelial cells. It is not clear if this enhancement of adhesion by the C4BP coating occurs by activating other Candida adhesins or by acting as a bridge.
Cell wall carbohydrate adhesin candidates.
The outer cell wall proteins of Candida are heavily glycosylated with N- or O-linked mannosyl residues and have been found to be strongly involved in the recognition of C. albicans by the innate immune system (58). Indeed, some of these sugar residues provide conserved Candida-associated chemical signatures, known as pathogen-associated molecular patterns, by which the host is able to recognize the presence of the pathogen via host pattern recognition receptors (PRRs). In recent years, it has become apparent that specific host PRRs bind to and recognize specific mannosyl residues on C. albicans. For example, the mannose receptor (MR) recognizes and binds to N-linked mannosyl residues (81), while Toll-like receptor 4 (TLR-4) binds O-linked mannosyl residues (3, 59, 60, 74). Similarly, TLR-2 recognizes and binds phospholipomannan (42), and galectin-3 binds β-mannosides (41). As these mannosyl residues are part of the structure of the cell wall, they are expressed on all three different morphological forms of C. albicans. However, there is evidence to suggest that there are differences in the recognition of yeast and hyphae by TLR-2 and TLR-4 (77).
Although these PRRs are principally involved in the recognition of C. albicans by components of the host immune response, it is also possible that they are used by C. albicans to adhere to and transmigrate across the endothelial lining of blood vessels. Indeed, several studies have demonstrated the important role of the TLRs in experimental models of disseminated candidiasis. Netea et al. showed that TLR-4-defective C3H/HeJ mice have an increased susceptibility to disseminated candidiasis (60), and mice deficient in the universal TLR adaptor protein myeloid differentiation factor 88 (MyD88) are extremely susceptible to C. albicans infection (78). However, it has also been shown that TLR-4-deficient mice are more resistant to disseminated Candida infection (3). This is also the case for TLR-2-deficient mice, which have also been shown to be more resistant to disseminated candidiasis (60). However, the majority of the literature on knockout mice and disseminated candidiasis looks at susceptibility to infection and correlates it with the immune response without focusing on receptor expression on endothelial cells. To date, endothelial cells have been shown to express a number of PRRs, including the MR, TLRs, and galectins. The MR was the first receptor on the surfaces of macrophages to be described as a mannan receptor, and it recognizes oligosaccharides that terminate in mannose, fucose, and N-acetylglucosamine. It is also expressed on subtypes of dendritic cells and endothelial cells from certain vascular beds, including human dermal microvascular endothelial cells but not human umbilical vein endothelial cells (31). So far, 10 TLRs have been found, of which 7 or 8 are expressed on unstimulated endothelial cells (23). However, upon stimulation with proinflammatory cytokines, all 10 TLRs are expressed. Perhaps most importantly for interactions with C. albicans, endothelial cells express TLR-2 and TLR-4 (61). TLR-4 is expressed constitutively at a higher level than that of TLR-2 by endothelial cells (17). However, the expression of both is significantly upregulated by stimulation with gamma interferon or bacterial lipopolysaccharide (18). It is also notable that the expression of TLR-2 on endothelial cells is strongly affected by the effects of flow on the endothelial cells (13). The galectins are a family of 15 carbohydrate binding proteins with high affinities for β-galactosides, extracellular glycoproteins, and glycolipids. So far, expression of galectin-1, -3, and -9 has been found on cultured endothelial cells (75), but only galectin-3 has been found to recognize C. albicans (41). Other PRRs that have been found to be involved in the recognition of C. albicans include DC-SIGN,
Mβ2, Fc
R, and dectin-1, but so far these receptors have not been found to be expressed on endothelial cells.
With so many different cell wall components having the potential to mediate adhesion of C. albicans to the endothelium, it seems that there could be a number of different mechanisms of adhesion. This may have consequences for the development of therapies aimed at blocking adhesion, because with so many molecules potentially playing a role, blocking only one could simply result in its role being taken up by other molecules. However, to investigate this further, more research is needed on the molecules involved in adhesion of C. albicans to the endothelial lining of blood vessels.

STATIC VERSUS FLOW ADHESION ASSAYS
The majority of the above studies that have directly explored
candidal adhesion to endothelium were performed by using static
in vitro assays where
C. albicans was left in prolonged contact
with cultured monolayers of endothelial cells. This is very
different from the fleeting interactions
C. albicans has with
endothelial cells under the conditions of shear stress and flow
that occur in blood vessels in vivo. Numerous studies with other
cells and microorganisms have shown that static assays do not
replicate the dynamic interactions that occur with endothelium
under conditions of flow and are poor at elucidating the contributions
of specific adhesion molecules (
29,
47). Only a few studies
have attempted to study candidal adhesion to synthetic substrata
under conditions of flow. These have shown that there are significant
differences in the adhesion of
Candida to the same substrata
when the assays are performed under static and flow conditions
(
8,
54). To date, only one study has attempted to examine the
adhesion of
Candida to endothelium under conditions of flow
(
29). Glee et al. found that under shear flow,
C. albicans formed
rapid, tight adhesions in less than 67 ms. This is much quicker
than in static assays and is comparable to the rapid adhesion
interactions that occur between leukocytes and endothelial cells.
In view of this, it is difficult to fully evaluate the contributions
of the mechanisms and adhesion molecules discussed above to
the adhesion of
C. albicans to endothelium in vivo, as none
have been studied under conditions of flow.

TRANSMIGRATION
After adhesion of
C. albicans to the endothelial lining of blood
vessels, the second step in the migration of
C. albicans from
the circulation into the tissues is transmigration across the
endothelial barrier. This step may involve some of the same
molecules used for adhesion but could involve others. Transmigration
is hard to research in isolation, which explains why there is
little information on specific methods of
Candida-endothelial
cell transmigration. Even so, there are several proposed mechanisms
for
Candida transmigration across the endothelium (Fig.
2).
The first mechanism proposes that endothelial cells endocytose
adherent organisms and allow their passage through to the abluminal
surface of the endothelial cell layer (Fig.
2, panel i). It
is this mechanism that has gained the most interest and for
which a model has evolved to explain how candidal hyphae adhere
to and then induce endothelial cells to endocytose them (
19,
21). In this model,
C. albicans hyphae bind to N-cadherin and
other, as yet unidentified proteins on the endothelial cell
surface via the candidal protein Als3 (
65). This adhesive interaction
induces tyrosine phosphorylation of unidentified intracellular
endothelial cell proteins (
2), causing microfilament rearrangement
to produce pseudopods, which initiate the endocytosis of adherent
hyphal forms of
C. albicans (
22,
65). However, endothelial endocytosis
of
C. albicans is not restricted to hyphal forms, and strains
that do not undergo hyphal change and cause little endothelial
cell damage are endocytosed to a significant degree (
40,
51,
64). Since the Als3 protein is predominantly expressed on candidal
hyphae (
65), this could involve other adhesin-endothelial ligand
pairs. There is also evidence that suggests that adherent yeast
forms could penetrate endothelial cells, damaging them in the
process, without undergoing morphogenetic change allowing them
to cross the endothelial barrier (
44). Another proposed mechanism
of
trans-endothelial cell migration of adherent
C. albicans involves the extension of penetrating hyphal processes through
the endothelial cells, likely destroying them in the process,
much as fungal hyphae ramify through other tissues (Fig.
2,
panel ii). Alternatively, a further proposal suggests that adherent
C. albicans cells may pass between adjacent endothelial cells
as a result of translocation and cyclical switching of adhesion
molecules at the junction between endothelial cells, in a manner
similar to that of leukocyte and tumor cell
trans-endothelial
cell migration (Fig.
2, panel iii).
Two alternative methods of transmigration across the endothelium
that may not require prior adhesion of
C. albicans to the endothelial
cell surface have also been proposed. The first mechanism proposes
that organisms phagocytosed by leukocytes are transported across
the endothelial barrier inside the leukocytes (Fig.
2, panel
iv). It is well known that leukocytes are able to cross the
endothelium, between adjacent endothelial cells, by diapedesis
and cyclical switching of adhesion molecules. Furthermore, there
is evidence of
C. albicans being found inside circulating leukocytes
in systemic candidiasis (
56). However, it is unlikely that this
represents the only mechanism for candidal transmigration, since
neutropenia is a major risk factor for invasive disease (
35,
46). The second mechanism, which may or may not require prior
adhesion, suggests that circulating
Candida cells simply pass
through endothelial fenestrations between adjacent endothelial
cells in vascular beds such as the kidney (Fig.
2, panel v).
Some of these mechanisms may operate only for the yeast, pseudohyphal, or hyphal form of C. albicans, some may work for all forms, and others may require morphogenetic change for transmigration to occur. As with C. albicans adhesion to endothelial cells, there is clearly much more research required in order to elucidate the precise mechanism by which C. albicans migrates across the endothelium and into the tissues. Additionally, as with leukocyte and tumor cell transmigration, the validity of these mechanisms may become apparent only when transmigration is studied in vivo or in situations where the endothelium is subject to conditions of flow (29, 47).

CONCLUSION
In summary, the interaction of
C. albicans with the endothelial
lining of blood vessels and its invasion of the tissues involve
a complex series of processes that is further complicated by
the role played by the morphogenetic conversion of
C. albicans.
There is still a large amount of work required to clarify these
processes. Furthermore, it is important that this work be performed
under conditions that replicate the fleeting contacts of
C. albicans with the endothelium and the dynamic conditions of
flow that occur in vivo. Nonetheless, understanding these mechanisms
may be critical in identifying a means for preventing
Candida invasion of the tissues and its lethal sequelae in systemic
candidiasis.

ACKNOWLEDGMENTS
The work presented here was funded in part by grant R21 AI065549-01A1
from the National Institute of Allergy and Infectious Diseases
to M.H.T.
The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

FOOTNOTES
* Corresponding author. Mailing address: Department of Oral & Maxillofacial Medicine and Surgery, School of Clinical Dentistry, 19 Claremont Crescent, Sheffield S10 2TA, United Kingdom. Phone: 44 114 2717849. Fax: 44 114 2717863. E-mail:
s.grubb{at}sheffield.ac.uk 
Published ahead of print on 23 June 2008. 
Editor: J. B. Kaper

REFERENCES
1 - Baine, W. B., M. G. Koenig, and J. S. Goodman. 1974. Clearance of Candida albicans from the bloodstream of rabbits. Infect. Immun. 10:1420-1425.[Abstract/Free Full Text]
2 - Belanger, P. H., D. A. Johnston, R. A. Fratti, M. Zhang, and S. G. Filler. 2002. Endocytosis of Candida albicans by vascular endothelial cells is associated with tyrosine phosphorylation of specific host cell proteins. Cell. Microbiol. 4:805-812.[CrossRef][Medline]
3 - Bellocchio, S., C. Montagnoli, S. Bozza, R. Gaziano, G. Rossi, S. S. Mambula, A. Vecchi, A. Mantovani, S. M. Levitz, and L. Romani. 2004. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J. Immunol. 172:3059-3069.[Abstract/Free Full Text]
4 - Bendel, C. M., D. J. Hess, R. M. Garni, M. Henry-Stanley, and C. L. Wells. 2003. Comparative virulence of Candida albicans yeast and filamentous forms in orally and intravenously inoculated mice. Crit. Care Med. 31:501-507.[CrossRef][Medline]
5 - Bodey, G. P., M. Buckley, Y. S. Sathe, and E. J. Freireich. 1966. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann. Intern. Med. 64:328-340.[Abstract/Free Full Text]
6 - Braun, B. R., W. S. Head, M. X. Wang, and A. D. Johnson. 2000. Identification and characterization of TUP1-regulated genes in Candida albicans. Genetics 156:31-44.[Abstract/Free Full Text]
7 - Braun, B. R., and A. D. Johnson. 1997. Control of filament formation in Candida albicans by the transcriptional repressor TUP1. Science 277:105-109.[Abstract/Free Full Text]
8 - Busscher, H. J., and H. C. van der Mei. 1995. Use of flow chamber devices and image analysis methods to study microbial adhesion. Methods Enzymol. 253:455-477.[Medline]
9 - Calderone, R., and P. C. Braun. 1991. Adherence and receptor relationships of Candida albicans. Microbiol. Rev. 55:1-20.[Abstract/Free Full Text]
10 - Clark, E. A., and J. S. Brugge. 1995. Integrins and signal transduction pathways: the road taken. Science 268:233-239.[Abstract/Free Full Text]
11 - Cole, G. T., A. A. Halawa, and E. J. Anaissie. 1996. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin. Infect. Dis. 22:S73-S88.[Medline]
12 - Cutler, J. E. 2001. N-glycosylation of yeast, with emphasis on Candida albicans. Med. Mycol. 39:75-86.[Medline]
13 - Dunzendorfer, S., H. K. Lee, and P. S. Tobias. 2004. Flow-dependent regulation of endothelial Toll-like receptor 2 expression through inhibition of SP1 activity. Circ. Res. 95:684-691.[Abstract/Free Full Text]
14 - Eigentler, A., T. F. Schulz, C. Larcher, E. M. Breitwieser, B. L. Myones, A. L. Petzer, and M. P. Dierich. 1989. C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect. Immun. 57:616-622.[Abstract/Free Full Text]
15 - Ernst, J. F., and S. K. Prill. 2001. O-glycosylation. Med. Mycol. 39:67-74.[Medline]
16 - Evans, Z. A., and D. N. Mardon. 1977. Organ localization in mice challenged with a typical Candida albicans strain and a pseudohyphal variant. Proc. Soc. Exp. Biol. Med. 155:234-238.[CrossRef][Medline]
17 - Faure, E., O. Equils, P. A. Sieling, L. Thomas, F. X. Zhang, C. J. Kirschning, N. Polentarutti, M. Muzio, and M. Arditi. 2000. Bacterial lipopolysaccharide activates NF-kappaB through Toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J. Biol. Chem. 275:11058-11063.[Abstract/Free Full Text]
18 - Faure, E., L. Thomas, H. Xu, A. Medvedev, O. Equils, and M. Arditi. 2001. Bacterial lipopolysaccharide and IFN-
induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-
B activation. J. Immunol. 166:2018-2024.[Abstract/Free Full Text] 19 - Filler, S. G. 2006. Candida-host cell receptor-ligand interactions. Curr. Opin. Microbiol. 9:333-339.[CrossRef][Medline]
20 - Filler, S. G., B. O. Ibe, P. M. Luckett, J. U. Raj, and J. E. J. Edwards. 1991. Candida albicans stimulates endothelial cell eicosanoid production. J. Infect. Dis. 164:928-935.[Medline]
21 - Filler, S. G., and D. C. Sheppard. 2006. Fungal invasion of normally non-phagocytic host cells. PLoS Pathog. 2:e129.[CrossRef][Medline]
22 - Filler, S. G., J. N. Swerdloff, C. Hobbs, and P. M. Luckett. 1995. Penetration and damage of endothelial cells by Candida albicans. Infect. Immun. 63:976-983.[Abstract]
23 - Fitzner, N., S. Clauberg, F. Essmann, J. Liebmann, and V. Kolb-Bachofen. 2008. Human skin endothelial cells can express all 10 TLR genes and respond to respective ligands. Clin. Vaccine Immunol. 15:138-146.[Abstract/Free Full Text]
24 - Fu, Y., A. S. Ibrahim, D. C. Sheppard, Y. C. Chen, S. W. French, J. E. Cutler, S. G. Filler, and J. E. J. Edwards. 2002. Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol. Microbiol. 44:61-72.[CrossRef][Medline]
25 - Fu, Y., G. Rieg, W. A. Fonzi, P. H. Belanger, J. E. J. Edwards, and S. G. Filler. 1998. Expression of the Candida albicans gene ALS1 in Saccharomyces cerevisiae induces adherence to endothelial and epithelial cells. Infect. Immun. 66:1783-1786.[Abstract/Free Full Text]
26 - Gantner, B. N., R. M. Simmons, and D. M. Underhill. 2005. Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments. EMBO J. 24:1277-1286.[CrossRef][Medline]
27 - Ghannoum, M. A., S. G. Filler, A. S. Ibrahim, Y. Fu, and J. E. J. Edwards. 1992. Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B. Antimicrob. Agents Chemother. 36:2239-2244.[Abstract/Free Full Text]
28 - Gilmore, B. J., E. M. Retsinas, J. S. Lorenz, and M. K. Hostetter. 1988. An iC3b receptor on Candida albicans: structure, function, and correlates for pathogenicity. J. Infect. Dis. 157:38-46.[Medline]
29 - Glee, P. M., J. E. Cutler, E. E. Benson, R. F. Bargatze, and K. C. Hazen. 2001. Inhibition of hydrophobic protein-mediated Candida albicans attachment to endothelial cells during physiologic shear flow. Infect. Immun. 69:2815-2820.[Abstract/Free Full Text]
30 - Gow, N. A., A. J. Brown, and F. C. Odds. 2002. Fungal morphogenesis and host invasion. Curr. Opin. Microbiol. 5:366-371.[CrossRef][Medline]
31 - Groger, M., W. Holnthoner, D. Maurere, S. Lechleitner, K. Wolff, B. B. Mayr, W. Lubitz, and P. Petzelbauer. 2000. Dermal microvascular endothelial cells express the 180-kDa macrophage mannose receptor in situ and in vitro. J. Immunol. 165:5428-5434.[Abstract/Free Full Text]
32 - Gustafson, K. S., G. M. Vercellotti, C. M. Bendel, and M. K. Hostetter. 1991. Molecular mimicry in Candida albicans. Role of an integrin analogue in adhesion of the yeast to human endothelium. J. Clin. Investig. 87:1896-1902.[CrossRef][Medline]
33 - Haas, T. A., and E. F. Plow. 1994. Integrin-ligand interactions: a year in review. Curr. Opin. Cell Biol. 6:656-662.[CrossRef][Medline]
34 - Hawser, S. P., and L. J. Douglas. 1994. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect. Immun. 62:915-921.[Abstract/Free Full Text]
35 - Hope, W. W., G. L. Drusano, C. B. Moore, A. Sharp, A. Louie, T. J. Walsh, D. W. Denning, and P. A. Warn. 2007. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob. Agents Chemother. 51:285-295.[Abstract/Free Full Text]
36 - Hostetter, M. K. 1994. Adhesins and ligands involved in the interaction of Candida spp. with epithelial and endothelial surfaces. Clin. Microbiol. Rev. 7:29-42.[Abstract/Free Full Text]
37 - Hostetter, M. K., J. S. Lorenz, L. Preus, and K. E. Kendrick. 1990. The iC3b receptor on Candida albicans: subcellular localization and modulation of receptor expression by glucose. J. Infect. Dis. 161:761-768.[Medline]
38 - Iannini, P. B., G. D. Arai, and F. M. LaForce. 1977. Vascular clearance of blastospore and pseudomycelial phase Candida albicans. Sabouraudia 15:201-205.[Medline]
39 - Jackson, D. E. 2003. The unfolding tale of PECAM-1. FEBS Lett. 540:7-14.[CrossRef][Medline]
40 - Jong, A. Y., M. F. Stins, S. H. Huang, S. H. Chen, and K. S. Kim. 2001. Traversal of Candida albicans across human blood-brain barrier in vitro. Infect. Immun. 69:4536-4544.[Abstract/Free Full Text]
41 - Jouault, T., M. El Abed-El Behi, M. Martinez-Esparza, L. Breuih, P. A. Trinel, M. Chamaillard, F. Trottein, and D. Poulain. 2006. Specific recognition of Candida albicans by macrophages requires galectin-3 to discriminate Saccharomyces cerevisiae and needs association with TLR2 for signaling. J. Immunol. 177:4679-4687.[Abstract/Free Full Text]
42 - Jouault, T., S. Ibata-Ombetta, O. Takeuchi, P. A. Trinel, P. Sacchetti, P. Lefebvre, S. Akira, and D. Poulain. 2003. Candida albicans phospholipomannan is sensed through Toll-like receptors. J. Infect. Dis. 188:165-172.[CrossRef][Medline]
43 - Kimura, L. H., and N. N. Pearsall. 1980. Relationship between germination of Candida albicans and increased adherence to human buccal epithelial cells. Infect. Immun. 28:464-468.[Abstract/Free Full Text]
44 - Klotz, S. A., D. J. Drutz, J. L. Harrison, and M. Huppert. 1983. Adherence and penetration of vascular endothelium by Candida yeasts. Infect. Immun. 42:374-384.[Abstract/Free Full Text]
45 - Klotz, S. A., and R. L. Smith. 1991. A fibronectin receptor on Candida albicans mediates adherence of the fungus to extracellular matrix. J. Infect. Dis. 163:604-610.[Medline]
46 - Koh, A. Y., J. R. Kohler, K. T. Coggshall, N. Van Rooijen, and G. B. Pier. 2008. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog. 4:e35.[CrossRef][Medline]
47 - Lawrence, M. B. 1999. Selectin-carbohydrate interactions in shear flow. Curr. Opin. Chem. Biol. 3:659-664.[CrossRef][Medline]
48 - Lee, K. H., M. S. Yoon, and W. H. Chun. 1997. The effects of monoclonal antibodies against iC3b receptors in mice with experimentally induced disseminated candidiasis. Immunology 92:104-110.[CrossRef][Medline]
49 - Lloyd, K. L., and P. Kubes. 2006. GPI-linked endothelial CD14 contributes to the detection of LPS. Am. J. Physiol. Heart Circ. Physiol. 291:H473-H481.[Abstract/Free Full Text]
50 - Lo, H. J., J. R. Kohler, B. DiDomenico, D. Loebenberg, A. Cacciapuoti, and G. R. Fink. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 1997:939-949.
51 - Lossinsky, A. S., A. Jong, M. Fiala, M. Mukhtar, K. F. Buttle, and M. Ingram. 2006. The histopathology of Candida albicans invasion in neonatal rat tissues and in the human blood-brain barrier in culture revealed by light, scanning, transmission and immunoelectron microscopy. Histol. Histopathol. 21:1029-1041.[Medline]
52 - MacCallum, D. M., and F. C. Odds. 2005. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 48:151-161.[CrossRef][Medline]
53 - Meri, T., A. M. Blom, A. Hartmann, D. Lenk, S. Meri, and P. F. Zipfel. 2004. The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect. Immun. 72:6633-6641.[Abstract/Free Full Text]
54 - Millsap, K. W., R. Bos, H. J. Busscher, and H. C. van der Mei. 1999. Surface aggregation of Candida albicans on glass in the absence and presence of adhering Streptococcus gordonii in a parallel-plate flow chamber: a surface thermodynamical analysis based on acid-base interactions. J. Colloid Interface Sci. 212:495-502.[CrossRef][Medline]
55 - Mouy, R., A. Fischer, E. Vilmer, R. Seger, and C. Griscelli. 1989. Incidence, severity and prevention of infections in chronic granulomatous disease. J. Pediatr. 114:555-560.[CrossRef][Medline]
56 - Nadir, E., and M. Kaufshtein. 2005. Images in clinical medicine. Candida albicans in a peripheral-blood smear. N. Engl. J. Med. 353:e9.[Free Full Text]
57 - Netea, M. G., G. D. Brown, B. J. Kullberg, and N. A. Gow. 2008. An integrated model of the recognition of Candida albicans by the innate immune system. Nat. Rev. Microbiol. 6:67-78.[CrossRef][Medline]
58 - Netea, M. G., N. A. Gow, C. A. Munro, S. Bates, C. Collins, G. Ferwerda, R. P. Hobson, G. Bertram, H. B. Hughes, T. Jansen, L. Jacobs, E. T. Buurman, K. Gijzen, D. L. Williams, R. Torensma, A. McKinnon, D. M. MacCallum, F. C. Odds, J. W. M. Van der Meer, A. J. P. Brown, and B. J. Kullberg. 2006. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J. Clin. Investig. 116:1642-1650.[CrossRef][Medline]
59 - Netea, M. G., C. A. Van Der Graaf, J. W. M. Van der Meer, and B. J. Kullberg. 2004. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J. Leukoc. Biol. 75:749-755.[Abstract/Free Full Text]
60 - Netea, M. G., C. A. Van Der Graaf, A. G. Vonk, I. Verschueren, J. W. M. Van Der Meer, and B. J. Kullberg. 2002. The role of Toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis. 185:1483-1489.[CrossRef][Medline]
61 - Opitz, B., S. Hippenstiel, J. Eitel, and N. Suttorp. 2007. Extra- and intracellular innate immune recognition in endothelial cells. Thromb. Haemost. 98:319-326.[Medline]
62 - Parker, J. C. J., J. J. McCloskey, and K. A. Knauer. 1976. Pathobiologic features of human candidiasis. A common deep mycosis of the brain, heart and kidney in the altered host. Am. J. Clin. Pathol. 65:991-1000.[Medline]
63 - Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs and modes of transmission. Clin. Infect. Dis. 22:S89-S94.[Medline]
64 - Phan, Q. T., P. H. Belanger, and S. G. Filler. 2000. Role of hyphal formation in interactions of Candida albicans with endothelial cells. Infect. Immun. 68:3485-3490.[Abstract/Free Full Text]
65 - Phan, Q. T., C. L. Myers, Y. Fu, D. C. Sheppard, M. R. Yeaman, W. H. Welch, A. S. Ibrahim, J. E. J. Edwards, and S. G. Filler. 2007. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol. 5:e64.[CrossRef][Medline]
66 - Rotrosen, D., J. E. J. Edwards, T. R. Gibson, J. C. Moore, A. H. Cohen, and I. Green. 1985. Adherence of Candida to cultured vascular endothelial cells: mechanisms of attachment and endothelial cell penetration. J. Infect. Dis. 152:1264-1274.[Medline]
67 - Sanchez, A. A., D. A. Johnston, C. Myers, J. E. J. Edwards, A. P. Mitchell, and S. G. Filler. 2004. Relationship between Candida albicans virulence during experimental hematogenously disseminated infection and endothelial cell damage in vitro. Infect. Immun. 72:598-601.[Abstract/Free Full Text]
68 - Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.[CrossRef][Medline]
69 - Santoni, G., R. Lucciarini, C. Amantini, J. Jacobelli, E. Spreghini, P. Ballarini, M. Piccoli, and A. Gismondi. 2002. Candida albicans expresses a focal adhesion kinase-like protein that undergoes increased tyrosine phosphorylation upon yeast cell adhesion to vitronectin and the EA.hy 926 human endothelial cell line. Infect. Immun. 70:3804-3815.[Abstract/Free Full Text]
70 - Santoni, G., E. Spreghini, R. Lucciarini, C. Amantini, and M. Piccoli. 2001. Involvement of alpha(v)beta3 integrin-like receptor and glycosaminoglycans in Candida albicans germ tube adhesion to vitronectin and to a human endothelial cell line. Microb. Pathog. 31:159-172.[CrossRef][Medline]
71 - Saville, S. P., A. L. Lazzell, C. Monteagudo, and J. L. Lopez-Ribot. 2003. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot. Cell 2:1053-1060.[Abstract/Free Full Text]
72 - Sheppard, D. C., M. R. Yeaman, W. H. Welch, Q. T. Phan, Y. Fu, A. S. Ibrahim, S. G. Filler, M. Zhang, A. J. Waring, and J. E. J. Edwards. 2004. Functional and structural diversity in the Als protein family of Candida albicans. J. Biol. Chem. 279:30480-30489.[Abstract/Free Full Text]
73 - Spreghini, E., A. Gismondi, M. Piccoli, and G. Santoni. 1999. Evidence for alphavbeta3 and alphavbeta5 integrin-like vitronectin (VN) receptors in Candida albicans and their involvement in yeast cell adhesion to VN. J. Infect. Dis. 180:156-166.[CrossRef][Medline]
74 - Tada, H., E. Nemoto, H. Shimauchi, T. Watanabe, T. Mikami, T. Matsumoto, N. Ohno, H. Tamura, K. Shibata, S. Akashi, K. Miyake, S. Sugawara, and H. Takada. 2002. Saccharomyces cerevisiae and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol. Immunol. 46:503-512.[Medline]
75 - Thijssen, V. L., F. Poirier, L. G. Baum, and A. W. Griffioen. 2007. Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood 110:2819-2827.[Abstract/Free Full Text]
76 - Todeschini, G. T. 1997. Treatment of candidiasis: a perspective on recent advances and future challenges. Int. J. Infect. Dis. 1:S37-S41.
77 - van Der Graaf, C. A., M. G. Netea, I. Verschueren, J. W. M. van der Meer, and B. J. Kullberg. 2005. Differential cytokine production and Toll-like receptor signaling pathways by Candida albicans blastoconidia and hyphae. Infect. Immun. 73:7458-7464.[Abstract/Free Full Text]
78 - Villamon, E., D. Gozalbo, P. Roig, C. Murciano, J. E. O'Connor, D. Fradelizi, and M. L. Gil. 2004. Myeloid differentiation factor 88 (MyD88) is required for murine resistance to Candida albicans and is critically involved in Candida-induced production of cytokines. Eur. Cytokine Netw. 15:263-271.[Medline]
79 - Wilson, L. S., C. M. Reyes, M. Stolpman, J. Speckman, K. Allen, and J. Beney. 2002. The direct cost and incidence of systemic fungal infections. Value Health 5:26-34.[CrossRef][Medline]
80 - Wurzner, R., M. Langgartner, L. Spotl, A. Eder, H. Bujdakova, K. Schroppel, and M. P. Dierich. 1996. Temperature-dependent surface expression of the beta-2-integrin analogue of Candida albicans and its role in adhesion to the human endothelium. Exp. Clin. Immunogenet. 13:161-172.[Medline]
81 - Yamamoto, Y., T. W. Klein, and H. Friedman. 1997. Involvement of mannose receptor in cytokine interleukin-1β (IL-1β), IL-6, and granulocyte-macrophage colony-stimulating factor responses, but not in chemokine macrophage inflammatory protein 1β (MIP-1β), MIP-2, and KC responses, caused by attachment of Candida albicans to macrophages. Infect. Immun. 65:1077-1082.[Abstract]
82 - Yokomura, I., Y. Iwasaki, K. Nagata, M. Nakanishi, A. Natsuhara, H. Harada, Y. Kubota, and M. Ueda. 2001. Role of intercellular adhesion molecule 1 in acute lung injury induced by candidemia. Exp. Lung Res. 27:417-431.[Medline]
83 - Zhao, X., S. H. Oh, G. Cheng, C. B. Green, J. A. Nuessen, K. Yeater, R. P. Leng, A. J. Brown, and L. L. Hoyer. 2004. ALS3 and ALS8 represent a single locus that encodes a Candida albicans adhesin; functional comparisons between Als3p and Als1p. Microbiology 150:2415-2428.[Abstract/Free Full Text]
84 - Zhao, X., S. H. Oh, and L. L. Hoyer. 2007. Deletion of ALS5, ALS6 or ALS7 increases adhesion of Candida albicans to human vascular endothelial and buccal epithelial cells. Med. Mycol. 45:429-434.[CrossRef][Medline]
85 - Zhao, X., S. H. Oh, and L. L. Hoyer. 2007. Unequal contribution of ALS9 alleles to adhesion between Candida albicans and human vascular endothelial cells. Microbiology 153:2342-2350.[Abstract/Free Full Text]
86 - Zhao, X., S. H. Oh, K. Yeater, and L. L. Hoyer. 2005. Analysis of the Candida albicans Als2p and Als4p adhesins suggests the potential for compensatory function within the Als family. Microbiology 151:1619-1630.[Abstract/Free Full Text]
Infection and Immunity, October 2008, p. 4370-4377, Vol. 76, No. 10
0019-9567/08/$08.00+0 doi:10.1128/IAI.00332-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Grubb, S. E. W., Murdoch, C., Sudbery, P. E., Saville, S. P., Lopez-Ribot, J. L., Thornhill, M. H.
(2009). Adhesion of Candida albicans to Endothelial Cells under Physiological Conditions of Flow. Infect. Immun.
77: 3872-3878
[Abstract]
[Full Text]